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Abstract
Background: By testing children and adolescents of HIV positive caretakers, index-linked HIV testing, a targeted HIV
testing strategy, has the ability to identify high risk children and adolescents earlier and more efficiently, compared
to blanket testing. We evaluated the incremental cost of integrating index-linked HIV testing via three modalities
into HIV services in Zimbabwe.
Methods: A mixture of bottom-up and top-down costing was employed to estimate the provider cost per test and
per HIV diagnosis for 2–18 year olds, through standard of care testing, and the incremental cost of index-linked HIV
testing via three modalities: facility-based testing, home-based testing by a healthcare worker, and testing at home
by the caregiver using an oral mucosal transudate test. In addition to interviews, direct observation and study
process data, facility registries were abstracted to extract outcome data and resource use. Costs were converted to
2019 constant US$.
Results: The average cost per standard of care test in urban facilities was US$5.91 and US$7.15 at the rural facility.
Incremental cost of an index-linked HIV test was driven by the uptake and number of participants tested. The
lowest cost approach in the urban setting was home-based testing (US$6.69) and facility-based testing at the rural
clinic (US$5.36). Testing by caregivers was almost always the most expensive option (rural US$62.49, urban
US$17.49).
Conclusions: This is the first costing analysis of index-linked HIV testing strategies. Unit costs varied across sites and
with uptake. When scaling up, alternative testing solutions that increase efficiency such as index-linked HIV testing
of the entire household, as opposed to solely targeting children/adolescents, need to be explored.
Keywords: HIV, Index-linked HIV testing, Community-based HIV testing, Home-based HIV testing, HIV assisted-
testing , Costing analysis
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Background
Since 2010, 1.4 million new HIV infections in children
have been averted worldwide, while HIV mortality
among children has halved [1, 2]. Despite this progress,
150,000 children were newly infected in 2019, falling
short of the 2018 target to reduce new HIV infections in
children to 40,000 [3]. In addition, HIV treatment cover-
age among children is significantly lower than among
adults, likely due to higher levels of under-diagnosis [4].
Furthermore, many children present to clinical services
and start antiretroviral therapy (ART) in older childhood
and adolescence when they have developed advanced
disease, with consequent poorer outcomes [5]. Notably,
adolescents are the only age-group in whom HIV-related
mortality has not declined [5–8]. HIV testing and coun-
selling approaches aimed at the timely diagnosis and
linkage to care of children and adolescents in high HIV
prevalence settings are therefore urgently needed.
Index-linked testing refers to screening family, house-
hold or other contacts of a case for a disease. Index-
linked HIV testing has been widely used to identify
higher risk individuals, and thus a high-yielding strategy
for HIV testing [9]. In sub-Saharan Africa children and
adolescents living in households with known HIV-
positive adults are more likely to be HIV-positive, and
are often untested and untreated [9–11]. Index-linked
HIV testing (ILHIVT), whereby children living with
adults with HIV are targeted for testing, has the poten-
tial to identify high-risk, difficult to access children and
adolescents, and to improve yield [9, 12, 13].
While WHO guidelines recommend offering testing to
children of HIV-positive adults, countries in Eastern and
Southern Africa have yet to integrate this policy into rou-
tine service delivery [9, 12, 14]. The paucity of data on ef-
fectiveness, cost and cost-effectiveness of ILHIVT may be
one factor preventing its scale up. As there are no costing
studies of ILHIVT within sub-Saharan Africa, the cost im-
plications and cost-effectiveness of including this strategy
within HIV service delivery programs is unknown.
The Bridging the Gap in HIV testing and care for
Children in Zimbabwe (B-GAP) study assessed the ef-
fectiveness and cost of a multi-option ILHIVT strategy
in both urban and rural settings in Zimbabwe [14]. This
paper is the cost analysis of B-GAP estimating the cost
of providing standard of care (SoC) HIV testing –volun-
tary, facility based HIV testing and counselling (HTC) –
comparing to the incremental cost of different ILHIVT
strategies.
Methods
B-GAP HIV testing intervention
In the B-GAP study, individuals with HIV enrolled in
and attending care at study clinics, i.e. indexes, were
offered HIV testing for any children and adolescents
(aged 2–18 years) of unknown HIV status in their house-
hold by study staff. Indexes could choose one of three
testing options for the child (ren)/adolescent(s): Clinic-
based diagnostic testing using a rapid test; home-based
rapid diagnostic testing by a healthcare provider; or
home-based, caregiver-provider testing using an oral
mucosal transudate (OMT) test. All participants diag-
nosed with HIV were linked to care at their nearest
healthcare facility.
Study setting
ILHIVT was provided at 9 of the 36 primary health care
facilities in Bulawayo and Mangwe district in Matebele-
land South province in Zimbabwe, (6 urban, 3 rural) se-
lected based on size and accessibility [14]. Adult HIV
prevalence in both these provinces is approximately 20%
[14]. The facilities do not routinely employ ILHIVT.
Cost data collection took place at 2 urban facilities in
Bulawayo, and 1 rural facility located in the Mangwe,
sampled by convenience (Table 1).
Costing methods
We estimated the provider cost of facility level HIV test-
ing and the provision of index-linked testing, following
the Global Health Cost Consortium costing guidelines
[15]. A combination of bottom-up and top-down costing
was employed. First, we estimated the full cost of testing
and diagnosis of children and adolescents through SoC
facility testing for a 4-month time period before the B-
GAP intervention (May– August 2018). We then esti-
mated the incremental cost of ILHIVT and diagnosis of
participants (September– December 2018) at the same 3
clinics, provided by the three modalities: clinic, health-
care worker testing in the household, and caregiver-
testing in the household. Costs estimated included
personnel, consumables, overheads, building, equipment,
training, start-up and transaction costs, but excluded
any research related costs.
To gauge personnel time, we undertook a combination
of direct observation and face-to-face interviews with
clinic and B-GAP staff to quantify resources utilized to
deliver all HIV testing models. We used prospective
time-tracking diaries and direct observation to measure
human resource time spent on different activities. Ap-
pendix 1 provides a summarized breakdown of time
spent on ILHIVT activities. Prices of test kits were taken
from the National Pharmaceutical Corporation of
Zimbabwe (NatPharm), as specified by the centralized
Matebeleland South pharmacy system. Overheads and
other shared clinic costs were allocated to the testing ac-
tivities based on area of the clinic utilized by each de-
partment and patient load depending on the line item.
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All resources used were converted into costs using fi-
nancial data collected from B-GAP project accounts,
Bulawayo City Council and the district and provincial
medical offices in Matebeleland South. Salaries of study
staff who conducted ILHIVT, were substituted with
those of facility primary care counsellors who would
carry out this work in routine clinical settings. Equip-
ment, building, training and start-up costs were annual-
ized using expected length of life determined by WHO
cost effectiveness and strategic planning prices for trad-
able goods, and discounted at a rate of 3% [16]. Due to
the instability of the Zimbabwean currency, we esti-
mated costs in US dollars. We converted all real-time
gross settlement (RTGS) dollars, the Zimbabwean cur-
rency, into USD using the exchange rate at the time
when the financial data was provided, using the Reserve
Bank of Zimbabwe exchange rates [17]. All costs were
converted to 2019 constant USD using the GDP deflator
for the United States [18]. A detailed description of the
cost data collection methods is provided in Appendix 2
and 3.
Healthcare outputs
We used clinic registers to determine the outputs of the
standard facility-based HIV testing service including
numbers of: tests administered; HIV positive test results;
tests administered to 2–18 year olds; positive test results
among 2–18 year olds. We used B-GAP study data to
determine the outputs of the three ILHIVT modalities,
including the number of: index cases screened; children
and adolescents identified through index cases; children
and adolescents tested by the three modalities; HIV-
positive children and adolescents diagnosed.
Data analysis
Unit cost per SoC HIV test in clinics, and per diagnosis
at each clinic were calculated by dividing the total 4
month costs of testing at each clinic by the total number
of people tested, and the number identified as positive,
respectively. As no additional resources were consumed
at clinics to test children/adolescents we assumed the
cost per test to be the same as for adults.
The incremental cost of ILHIVT was calculated by
assessing the additional personnel time and resources to
follow-up cases and test them. To obtain the incremen-
tal cost per test, the incremental cost was divided by the
total number of children and adolescents who were
tested using the respective modality. The cost per diag-
nosis of a positive child/adolescent was calculated as the
incremental cost per test divided by the number who
tested positive. The relationship between uptake and
unit cost was explored by plotting the incremental ILHI
VT cost per test, against uptake per modality.
Sensitivity analysis
A univariate sensitivity analysis was performed on input
variables for which there was a degree of uncertainty, or
that constituted a significant portion of the total costs
including the exchange rate and transaction costs. The
impact of the RTGS conversion rate used (1USD:4
RTGS) was assessed by varying the conversion rate to
the highest (1USD:1 RTGS) and lowest (1USD: 50
RTGS) observed rates during the study period. The im-
pact of assumptions made around resource use items
such as staff salaries (±5–10%,), building (±10–20%),
equipment (±10–20%) and overhead costs (±10–20%)
and the frequency of the refresher training (1/year – 4/
year) were also tested. In addition, HIV prevalence of
clinic attendees was varied from 5 to 20%, while yield of
ILHIVT was varied from 2 to 7%. Finally, transaction
costs defined as management costs incurred through
non-governmental organization (NGO) supervision of
intervention activities (for study staff), was varied (±10–
20%).
Scenario analysis
HIV self-testing is recommended by the WHO as an al-
ternative HIV testing strategy for scale-up [19–21], and
qualitative work conducted after the conclusion of the
ILHIVT intervention indicated that lack of exposure to,
Table 1 Characteristics of costing study facilities, as of Sept 2018
Clinic A Clinic B Clinic C
District Bulawayo Bulawayo Mangwe
Setting Urban Urban Rural
Catchment Area Population Total 42,497 31,492 9137
Catchment Area Population Under 15 yrs 14,433 10,696 4066
Catchment Area Population 15 years + 28,063 20,796 5071
Overall Facility Visits in 1 Yeara 50,778 77,558 5118
HIV Tests Conducted in 1 Yeara 2541 3276 1860
Number of people on ART as of Sept 2018 4478 4625b 960
aBased on one year of facility registries: Oct 2017 – Sept 2018
bDue to missing records, this tally is current as of June 2017
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and acceptability of caregiver-provided testing affected
the uptake of this modality across all sites. We explored
variations in the uptake of index-linked caregiver pro-
vided HIV testing to reflect potential real-world accept-
ability and implementation scenarios: 1.) equal uptake of
all 3 modalities; 2.) a 50–50 split between facility based
testing and testing performed by caregivers; 3.) 100% up-
take of caregiver-provided testing at all clinics. Addition-
ally, we compared the efficiency of home-based and
caregiver-provided testing (i.e. non facility-based op-
tions) by identifying the uptake of caregiver provided
tests required to match the unit cost of home-based
ILHIVT performed by health care workers.
Results
Cost composition
Table 2 presents recurrent and capital costs for SoC
HIV testing and the three ILHIVT modalities. The total
monthly cost of providing SoC testing ranged from
US$997 to US$1410. Across these facilities, personnel
costs accounted for 56.9 to 70.9% of total costs; testing-
specific consumables accounted for 27.9 to 35.7%; over-
heads from 1.2 to 9.8%, and less than 1% of total costs
were attributable to capital resource items. The total in-
cremental monthly cost of providing ILHIVT ranged
from $379 to $400 in clinic; $359 to $420 for home-
based testing; $255 to $288 for caregiver-provided test-
ing. Across all three clinics and modalities; personnel
costs accounted for 39.7 to 62.4% of total costs; testing-
specific consumables accounted for 4.5 to 23.1%; trans-
action costs from 17.6 to 29.1%; capital resource items
for 2.6 to 6.4%.
HIV testing outcomes
From May 2018 to August 2018, 2317 clinic based SoC
HIV tests were administered (Table 3). The test yield
(proportion of test results that were positive), was 12.9%
(299/2317 total tested). Across the 3 clinics 11.5% (267/
2317) of those tested were 2–18 years of age, and the
yield was 3.7% (10/267).
The 3 clinics screened 2087 index-cases, identified
1708 eligible children and adolescents of unknown
HIV status, and of those, tested 1263 (74%); 41% in
clinic, 48% via home-based testing, and 10% through
assisted testing. Uptake of each modality varied by
clinic; home-based testing was the preferred option at
urban clinics A (45.7%) and B (65.9%), while clinic
testing was the preferred option at rural clinic C
(56.2%). The yield of ILHIVT at Clinics A, B and C
was 0.6% (3/505), 0.3% (1/290) and 1.5% (7/468) re-
spectively. Yield by modality is as follows: 1.3% (7/
523) via clinic; 0.5% (3/611) via home-based; 0.8% (1/
129) via caregiver-assisted testing (Table 3).
Unit costs
The cost per child/adolescent tested through SoC ranged
from US$5.90 to US$7.15. The cost per positive SoC test
result ranged from US$ 35.92 to US$61.61. The costs
per HIV-positive child or adolescent, 2–18 years of age
identified through SoC were US$166.69, US$139.76,
US$197.80 at Clinic A, B and C respectively (Table 3).
The average incremental cost per child/adolescent
tested through ILHIVT at the clinic ranged from
US$10.56 (urban clinic A) to US$25.47 (rural clinic C).
The incremental cost per modality across all clinics
ranged as follows: clinic – US$5.36 (clinic C) to
US$31.08 (clinic B); home-based testing by health care
worker – US$6.69 (clinic A) to US$8.65 (clinic C);
caregiver-provided testing – US$17.59 (clinic A) to
US$62.40 (clinic C). The cost per diagnosis of an HIV
positive child/adolescent through ILHIVT ranged from
US$352.59 to US$1492.02 for clinic based ILHIVT and
US$817.21 to US$1545.41 via home-based testing by
health care worker. Clinic C had the only positive test
result from caregiver-provided testing, which cost
US$998.41 (Table 3). The uptake of ILHIVT via modal-
ity and associated incremental cost per test indicates
that costs are likely dependent on quantity: the fewer
tests administered via modality, the higher the associated
incremental unit cost per test, and vice versa (Fig. 1).
Sensitivity analysis
All 4 HIV testing unit costs (SoC and ILHIVT via 3 mo-
dalities) were most sensitive to changes in the conver-
sion rate. Figures 2a – d present the results of the
sensitivity analysis performed on the remaining variables.
With regards to resource use inputs, personnel salaries
had the largest influence on SoC unit costs (±3–7%),
followed by overheads and the addition of up to 4 re-
fresher trainings. Changes to capital resource inputs had
a negligible effect on SoC unit costs. When considering
the resource use inputs for ILHIVT across all three mo-
dalities, the unit cost per test was most sensitive to
changes in clinic attendee HIV prevalence (±9–13%),
followed by personnel salaries for all 3 modalities .
The impact of changing the parameters on cost per
diagnosis unit costs are presented in Supplementary
Fig. 1. Cost per diagnoses were most sensitive to changes
in the conversion rate. Of the resource use inputs,
personnel costs had the largest influence on SoC unit
costs, while changes to clinic attendee HIV prevalence
as well as testing yield, had the largest influence on ILHI
VT related unit costs.
Scenario analysis
The results of varying modality uptake and the subse-
quent impact on unit cost per test, compared to ob-
served unit costs for the 4-month period in this study

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Vasantharoopan et al. BMC Health Services Research         (2021) 21:1082 Page 5 of 13
are presented in Table 4. If all 3 modalities have equal
uptake, the unit cost of home-based testing increases
and caregiver-provided testing becomes cheaper than
clinic testing at urban clinics. If clinic and caregiver-
provided testing have equal uptake, the unit cost of
clinic testing decreases at both urban clinics but in-
creases at the rural clinic, while unit costs of caregiver-
provided testing at all three clinics decrease substan-
tially. If all index-linked testing is via caregiver-provided
testing, the cost per test at Clinic A, B and C respect-
ively, are as follows: US$2.12, US$6.52, US$5.32.
In order for the caregiver – provided testing incremen-
tal unit cost per test to equate to that of ILHIVT via the
home-based testing modality observed in the same 4-
month time period, 163, 241 and 177 caregiver-provided
tests would need to be administered at clinics A, B and
C respectively. If all participants at clinics A and C who
chose home-based testing had opted for caregiver-
Table 3 Unit cost of the various HIV testing modalities across all three costing study clinics, over a 4 month time-period
Testing Modality No. Tested No. Positive Cost Per Test (USD) Cost Per Diagnosis (USD)
Clinic A – Bulawayo (Urban)
Standard of Care (SoC) – Total 804 77 $5.90 $61.61
SoC 2–18 years 113 4 $5.90 $166.69
Index-Linked-Clinic 212 2 $7.41 $785.50
Index-Linked-Home-Based 231 1 $6.69 $1545.41
Index-Linked-Caregiver 62 0 $17.59 N/A
Clinic B – Bulawayo (Urban)
Standard of Care – Total 955 157 $5.91 $35.92
SoC 2–18 years 71 3 $5.91 $139.76
Index-Linked-Clinic 48 1 $31.08 $1492.02
Index-Linked-Home-Based 191 0 $7.18 N/A
Index-Linked-Caregiver 51 0 $21.63 N/A
Clinic C – Mangwe (Rural)
Standard of Care – Total 558 65 $7.15 $61.37
SoC 2–18 years 83 3 $7.15 $197.80
Index-Linked-Clinic 263 4 $5.36 $352.59
Index-Linked-Home-Based 189 2 $8.65 $817.21
Index-Linked-Caregiver 16 1 $62.40 $998.41
1. Unit cost of SoC HIV testing presented for all clinics span May-Aug 2018 period
2. Incremental unit cost of index-linked testing for all modalities, presented for all clinics span Sep-Dec 2018
Fig. 1 Uptake of Index-Linked HIV Testing vs associated Incremental Cost per Test, according to modality: Clinic; Caregiver; Home-Based
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provided testing instead, it might have been possible to
observe the lower situational caregiver – provided test-
ing unit cost per test.
Discussion
Our findings show that 6 times more children/adolescents
were tested via ILHIVT compared to SoC HIV testing
over the observed period. HIV prevalence among chil-
dren/adolescents accessing SoC HIV testing (4%), was
much higher than children/adolescents (0.7%) tested via
ILHIVT. The cost of SoC HIV testing was lower in urban
than rural settings, due to a greater number of tests ad-
ministered at the urban clinics (44–71% more) and larger
catchment populations. The cost of ILHIVT modalities
were dependent on, and varied according to uptake. Costs
involved in delivering SoC HTS were primarily driven by
personnel followed by consumables. Whereas personnel
followed by transaction costs were the largest drivers of
ILHIVT costs at both urban and rural clinics. While man-
agement costs will be an important component of ensur-
ing quality as well as accountability in strategies such as
a b
c d
Fig. 2 a. Tornado plot of model parameters varied in univariate sensitivity analysis of Adolescent SoC HTS and impact on Cost per Test. b.
Tornado plot of model parameters varied in univariate sensitivity analysis of Index-Linked Testing via Clinic modality and impact on Cost per Test.
c. Tornado plot of model parameters varied in univariate sensitivity analysis of Index-Linked Testing via Home-Based modality and impact on Cost
per Test. d. Tornado plot of model parameters varied in univariate sensitivity analysis of Index-Linked Testing via Caregiver modality and impact
on Cost per Test
Table 4 Scenario analysis of varying index-linked modality
preference/uptake across all clinics: change in Unit Cost – Cost
per Test
Clinic Home-Based Caregiver
Clinic A – Original Unit Cost 7.41 6.69 17.79
Equal − 1/3 Distribution $9.10 $8.85 $6.36
50:50 –Clinic/Caregiver $6.37 N/A $4.24
Caregiver Only N/A N/A $2.12
Clinic B – Original Unit Cost 31.08 7.18 21.63
Equal −1/3 Distribution $15.89 $13.32 $12.97
50:50 –Clinic/Caregiver $10.89 N/A $9.75
Caregiver Only N/A N/A $6.52
Clinic C – Original Unit Cost 5.36 8.65 62.40
Equal −1/3 Distribution $8.42 $10.29 $9.36
50:50 –Clinic/Caregiver $5.92 N/A $7.34
Caregiver Only N/A N/A $5.32
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this that rely on identifying potential cases and outreach
to the community, the management of this type of service
delivery may need to be streamlined in an effort to keep
transaction costs low.
The cost of delivering HIV testing through standard
clinic-based services in this study ranged from US$5.90 to
US$7.15, and is comparable to recent STAR project esti-
mates from Malawi, Zambia and Zimbabwe (2016
US$4.24 to US$7.65) [22], yet higher compared to the re-
sults of a systematic review evaluating the cost of HTC in
South Africa (2017/2018 US$3.62) [23]. The cost per posi-
tive diagnosis through standard clinic services in this study
was lower than STAR estimates (US$73.63 to US$178.92)
and likely reflects the higher HIV prevalence of those
accessing testing among our study population (13%), com-
pared to the STAR project (7%) [22].
In contrast, the high cost per diagnosis associated with
ILHIVT was due to a low prevalence of HIV among
index-linked children. An estimated > 90% of children liv-
ing with HIV are vertically infected; those who were born
prior to the scale up of prevention of mother to child
transmission (PMTCT) programs are now likely to be ad-
olescents and would therefore be diagnosed only when
symptomatic, resulting in worse outcomes than those di-
agnosed and initiated on treatment in infancy [13, 24].
SoC HIV testing is likely to diagnose children with ad-
vanced disease, whereas asymptomatic children may not
be brought to the clinic. Other studies of the same age-
group in Zimbabwe found higher prevalence (2.6–15%)
[11, 25], and index-linked testing of sexual partners and
biological children in 3 rural provinces found a 30% HIV
prevalence [12]. A study in Cameroon where only 46.2%
of indexes consented to have their children tested, diag-
nosed HIV infection in 6.8% of children tested [24], while
another index-linked study in Lesotho found an HIV
prevalence of 1.8% among biological children of indexes
[26]. The low HIV prevalence among index cases at the B-
GAP clinics is likely attributable to recent HIV testing
campaigns potentially resulting in saturation of testing, in-
cluding a large Population Services International testing
campaign operating in the area and exclusion of children/
adolescents tested > 6months prior to B-Gap screening.
HIV case finding will become more costly as knowledge
of HIV status and treatment coverage increase. Alternative
community based HIV testing strategies such as home-
based testing and HIV Self-Test have been evaluated using
costing studies [19, 27, 28], but this is the first costing study
to evaluate index-linked testing, a strategy proposed by the
WHO in order to expand HTC [29]. Our results provide
the first unit costs of the different ILHVIT modalities for
sub-Saharan Africa but they do not provide information on
the cost-effectiveness of the strategy. While a full economic
evaluation is necessary to accurately estimate the cost-
effectiveness of ILHIVT, Phillips et al. (2019) have shown
that cost per diagnosis can be used as a proxy for cost-
effectiveness of HIV testing programs, and estimated a value
for the cost-effectiveness threshold (2018) US$315 per HIV
diagnosis [30]. By this definition, none of the index-linked
modalities in our analysis would be considered cost-effective
as the lowest cost per diagnosis estimated was US$385.35.
However, our sensitivity analysis illustrated that when ILHI
VT yield was increased from 0.7 to 7%, (as observed in
Cameroon [24]), all but two modalities (clinic testing at an
urban clinic, and rural caregiver-provided testing), resulted
in cost per diagnoses below that US$315 threshold. ILHIVT
cost per diagnosis would be more cost-effective if targeted
to a higher-prevalence population. For example, a more effi-
cient solution for scaling up ILHIVT could be to test the en-
tire household; costs would be shared across a greater
number of tests and yield would likely increase as adults
have a higher prevalence of HIV compared to children/ado-
lescents – although measures would need to be in place to
ensure services screen out those previously diagnosed and
on ART [27], and those testing are effectively linked to HIV
treatment or prevention. A scale-up of any version of ILHI
VT – in its current format, or expanded to the entire house-
hold – to either the regional or national level, requires care-
ful consideration of the implications of potential (dis)
economies of scale as well as other cost drivers. While this
study explored drivers of cost at the facility level, and ex-
pected uptake is critical to this setting, physical capacity and
infrastructure investment costs necessitate scrutiny at the
regional or national level [31]. Furthermore, costs involved
in geographical variability with regards to transport, training,
management, monitoring and evaluation, quality assurance,
as well as socio-cultural variability and acceptability affecting
demand, must be considered [32].
HIV self-testing has the advantages of convenience, dis-
cretion and confidentiality, compared to clinic based HTS
[33, 34]. HIV self-test has shown high acceptability and
uptake elsewhere which resulted in WHO guidelines
recommending scale-up [19–21]. In this study ‘self-test’
however referred to caregiver assisted testing of a child/
adolescent. Caregiver uncertainty about correctly adminis-
tering the test to a child without the aid of a health care
professional, as well as fear of how to counsel a child with
a positive result, could be factors accounting for the low
levels of uptake within this study [35]. SoC clinic based
HIV testing, when supplemented with HIV self-testing,
can be a cost-effective testing option in a population with
a high HIV prevalence and has the capacity to extend
coverage rates, and therefore diagnoses [28, 33]. In this
study, because assisted-testing had very low uptake, the in-
cremental unit costs were 3.0 times greater than the
cheapest modality (home–based) in an urban setting, and
11.6 times higher than the cheapest modality (clinic) in a
rural setting. This low uptake raises questions around the
differences of administering a self-test to someone else,
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compared to self-administration. Exploration into the dy-
namics and differences between HIV self-test and assisted
self-test are needed.
To our knowledge, this study is the first to estimate the
cost of ILHIVT in any setting. A limitation is that only 3
clinics were included. Although both urban and rural
clinics are represented, showing that the cost and effi-
ciency of each modality varies according to setting, it
should be noted that the urban and rural clinics were lo-
cated in different districts. While Bulawayo is an entirely
urban district, and Mangwe an entirely rural district, there
may be unique structural and/or district level factors
which also influence unit costs. Additionally, the study
was conducted within an economically unstable context.
Zimbabwe dollarized its economy in 2008 following
hyperinflation. In 2018 it introduced its own currency
(RTGS), which triggered rapid inflation. In this study all
RTGS amounts were converted to USD at the prevailing
rate. Costs were highly sensitive to conversion rate as a re-
sult of the rapid inflation of RTGS against the US dollar.
Conclusion
Innovative and alternative HIV testing strategies above
SoC approaches are necessary in order to reach children
and adolescents, given the additional barriers they face
in order to get tested. The results of our study confirm
that both costs and uptake of ILHIVT vary with setting.
In addition, while ILHIVT allows for greater access of
this difficult to reach population, compared to the stand-
ard method, uptake is a key driver of the cost per test.
To ensure efficiency when scaling up ILHIVT, accept-
ability of testing modality needs to be considered and al-
ternative index linked testing solutions that increase
yield such as ILHIVT of the entire household, as op-
posed to solely targeting children/adolescents, need to
be explored. Additionally, there is potential to benefit
from economies of scope by integrating ILHIVT with
other activities, however this would require further con-
sideration and research.
Appendix 1
Summary of time tracking diaries for ILHIVT activities:
compiled via direct observation and self-evaluation
Time tracking diaries completed by the costing team
through direct observation, as well as time tracking
diaries completed by research assistants through self-
evaluation had the same format: an activity code, a de-
scription of the activities and a table which divided the
workday into half hour increments. The following illus-
trates an abbreviated version of how human resource
use was delineated and recorded.
Instructions: Using the activity codes below, please
record the appropriate activity for each half hour
interval of your work day, over the course of one
consecutive week. If activities conducted do not fall
into one of the pre-listed activities below, please spe-
cify the activity in the blank codes (code 13–15), and




01 Organization/Administrative Activities (Ex. Preparing
CRFs for use the next day, photo copying, filing, filling out
petty cash ledger etc.)
02 Screening Index Cases, Including morning health talk and
evaluating self-testing competency
03 Testing Children/Adolescents of Index Cases
04 Filling out CRFs (All CRFs: Enrolment, Outcome, Locator,
etc.)
05 Follow-Up, including phone calls made for testing
reminders, initiating testing & following-up of results with
community partners, linking to treatment, enrolling in
CHW intervention, etc.
06 Outcome Assessment, including exit interview, sample
collection, sending sample out for processing
07 Meetings (Ex. With study coordinator; at clinic; with
community partners; with stakeholders)
08 Assisting clinic staff with non-B-Gap related tasks (Ex.
Testing O/I patients)
09 Breaks and Down-Time (Ex. During a slow day, waiting for
patients etc.)
10 Community Testing (Home Visits)
11 Travelling to households for community testing
12 Collection of Assisted Self-Test kits
13




A total of 56 direct observation hours and 535 self-
evaluation hours were recorded via the time tracking
diaries. Daily activity breakdown is classified into three
categories and presented below: Clinic Hours; Commu-
nity Hours; Administration
Allocation of Human Resource Use Involved in ILHIVT Activities:












C – Mangwe (Rural) 7.3% 22.8% 70.0%
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Appendix 2
Table 5 Detailed Description of Cost Resource Collection: Methods
Cost Category Primary Method of Data Collection Details
Recurrent Costs
Personnel HTS: Interviewing the Nurse-In-Charge
Index-Linked-Testing:
Interviews with the study coordinator and
research assistants, in addition to direct
observation
HTS:
- When all clinic staff was recorded, clinic staff time was measured through
direct observation, with a particular focus on the HTS.
- A PCC at each clinic was observed for a full work day, by two separate
individuals, and was also interviewed.
Index-Linked-Testing:
- Study personnel demarcate their time solely to index-linked testing activities.
As a result time-tracking diaries were completed by study personnel to detail
time spent on specific activities over the course of the study, and directly ob-
served while in clinic also.
- 6 research assistants completed diaries spanning 2 weeks each.
- Direct observation was completed by 2 separate individuals, observing each
of the 6 assistants for 1 day each.
Consumables HTS: Interviewing the primary care counsellors
Index-Linked-Testing:
Interviewing study research assistants
HTS: First, PCCs were asked to specify every consumable which was required
for an HTS client. Then each item was catalogued by natural unit – ex. 500 g
bag of absorbent cotton, 1 roll per bag. Following this, each consumable was
quantified per consumption length – ex. one pack of cotton lasts on average,
3.5 weeks. Use was then calculated monthly (ex. 1.14 pack/month), and
monthly use was then extrapolated to cover a one-year time period.
Index-Linked-Testing: Method, same as above.
Training HTS: Interviewing the Nurse-in-Charge/District
Medical Officer
Index-Linked-Testing: Abstracting study
accounting files and interview with study
coordinator.




Abstracting study accounting files
Frequency and amount of duties related to index-linked testing consumables
was noted.
Overheads HTS: Interviewing nurse-in-charge
Index-Linked-Testing: Abstracting study
accounting files
HTS: Overheads were collected and then apportioned according to HTS usage,
compared to the size of the other clinic departments.
Index-Linked-Testing: Abstracting study accounting files.
Lab-Processing Index-Linked-Testing (only):
Abstracting study accounting files





HTS: Direct observation and physically pacing/
spacing the clinic.
The area of the clinic and HTS were manually measured.
Furniture and
Equipment
HTS: Direct observation and recording
Index-Linked-Testing: Direct observation,
recording and abstracting study accounting files





Abstracting study accounting files
Frequency and financial resources invested in initial RA training, as well as RA
rapid diagnostic and OMT testing training, was noted.
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Appendix 3
Table 6 Detailed Description of Cost Resource Collection: Interviews
Interviewee Purpose
HTS
1 Nurse in Charge at each of the 3 clinics (supplemented by at least
one other RGN at each clinic)
To obtain:
- Rundown of all clinic personnel and their roles
- All inputs included in clinic overheads
1 Primary Care Counsellor at each of the three clinics To obtain:
- Activity breakdown of HTS
- Resource data collection involved in HTS
Assistant Director of Bulawayo City Council (BCC) and BCC finance
department
To obtain:
- Bulawayo clinic personnel salary schedule
- Costs per training/refresher training workshops related to HTS
- All overhead costs
Provincial Medical Director and MAT South finance department To obtain Mangwe clinic personnel salary schedule
District Medical Director (Mangwe) To obtain:
- Salary for district’s HIV focal person
- Costs per training/refresher training workshops related to HTS
District Environmental Health Officer (Mangwe) To obtain Mangwe clinic overhead costs
MAT South Pharmacist To obtain HTS consumable costs
Index-Linked Testing
Research Coordinator To understand overall flow of study, obtain outcome data, query
clarifications
6 Research Assistants; 2 at each of the three clinics To discern daily activity breakdown and recurrent resources consumed over
the course of study activities
BRTI Study Accountant To obtain all study related costs:
- RA salary schedule
- Study consumable costs
- Recurrent costs: Overheads and Training
BRTI Administrator To obtain equipment costs
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